CLIN CANCER RES：DC-CIK免疫治疗联合S-1化疗治疗晚期胰腺癌

2017-09-07 MedSci MedSci原创

晚期胰腺癌患者如何有效进行治疗一直是一个巨大的挑战。CLIN CANCER RES近期发表了一篇文章，研究DC-CIK免疫疗法联合S-1化疗治疗这种恶性疾病的安全性和临床效果。

晚期胰腺癌患者如何有效进行治疗一直是一个巨大的挑战。CLIN CANCER RES近期发表了一篇文章，研究DC-CIK免疫疗法联合S-1化疗治疗这种恶性疾病的安全性和临床效果。47例晚期胰腺癌患者分别接受DC-CIK+S-1，单独DC-CIK，单独S-1或支持治疗。研究结果表明，DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期（212和136天），单独DC-CIK（128和85天），单纯化疗为（141和92天），支持治疗（52和43天）。调整了危险因素后，DC-CIK联合S-1化疗以及接受2个周期及以上DC-CIK治疗是无病生存和总生存的独立预测因素。PBMCs亚型分析表明DC-CIK细胞治疗后CD3+，CD3+/CD4+以及CD8+/CD28+T细胞亚群增加，而CD3+/CD8+，CD3+/CD16+/CD56+和CD4+/CD25+细胞亚群显着下降。无3级或4级毒性反应。此外，14例接受DC-CIK治疗患者中4例出现循环肿瘤细胞DNA下降，且与生存改善有关。文章最后认为，DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的，可以改善患者无进展生存和总生存情况，并调节外周

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-10 luominglian113

学习了.谢谢分享

34 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-09 ms7899726347904398

#晚期胰腺癌#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-09 ms3117646317107274

#S-1#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-07 随梦飞扬

DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份.

48 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-07 随梦飞扬

单独DC-CIK(128和85天)

59 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-07 随梦飞扬

DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天)

34 0
[GetPortalCommentsPageByObjectIdResponse(id=242640, encodeId=80c824264003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:54:26 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389565, encodeId=f22e1389565da, content=<a href='/topic/show?id=82a95988106' target=_blank style='color:#2F92EE;'>#晚期胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59881, encryptionId=82a95988106, topicName=晚期胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477854, encodeId=86c914e7854a2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Sat Sep 09 00:44:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241497, encodeId=f4bc24149e6e, content=DC-CIK联合S-1化疗治疗晚期胰腺癌是安全的.可以改善患者无进展生存和总生存情况.并调节外周血免疫组份., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:30:58 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241495, encodeId=9aa624149596, content=单独DC-CIK(128和85天), beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:24:19 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241490, encodeId=c2612414900a, content=DC-CIK联合S-1化疗显着延长患者平均总生存期和无进展生存期(212和136天), beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Thu Sep 07 18:22:36 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241445, encodeId=7630241445bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Sep 07 12:04:34 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
2017-09-07 1ddf0692m34(暂无匿称)

学习了.涨知识

36 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：DC-CIK免疫治疗联合S-1化疗治疗晚期胰腺癌

相关资讯

科室

工具

服务